Rubraca Significantly Improves Survival Ovarian Cancer

(January 18, 2018)

CancerConnect News: According to the results of a recently published clinical trail the novel precision cancer medicine Rubraca® (rucaparib) improves the outcomes of individuals with advanced ovarian cancer. About Rubraca® Rubraca® is an oral taken... Continue Reading


Xgeva Approved for The Treatment of Multiple Myeloma

(January 17, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has expanded the approval of Xgeva (denosumab) for the prevention of skeletal-related events in patients with bone metastasis from multiple myeloma. In multiple myeloma, plasma cells infiltrate... Continue Reading


Keytruda in Combination with Alimta and Platinum Chemotherapy Improves Survival in Non Small Cell Lung Cancer

(January 17, 2018)

CancerConnect News: Keytruda (pembrolizumab) is the first PD1 Inhibitor to demonstrate improved overall survival when combined with chemotherapy as primary treatment for metastatic non-squamous non-small cell lung cancer (NSCLC). The KEYNOTE-189 clinical... Continue Reading


Ovarian Cancer: Doctors at Sloan Kettering Explore Immunotherapy

(January 16, 2018)

CancerConnect News:  All gynecologic cancers are challenging to treat. They can be hard to find and are usually diagnosed when they are advanced. Although these cancers can be held at bay with surgery or chemotherapy, they often return and become difficult... Continue Reading


Lynparza Slows Spread of Inherited Breast Cancer Caused by BRCA Mutations: First Drug Approved for BRCA Breast Cancer

(January 15, 2018)

CancerConnect News: The US Food and Drug Administration (FDA) has extended the approval of Lynparza (olaparib) to include the treatment of metastatic breast cancer in patients who carry the specific inherited BRCA mutation.  These patients can be identified... Continue Reading


Keytruda Significantly Improved Recurrence-Free Survival in Patients with Stage 3 Melanoma

(January 15, 2018)

CancerConnect News:  The European Organisation for Research and Treatment of Cancer (EORTC), today announced that the phase 3 EORTC1325/KEYNOTE-054 trial investigating Keytruda (pembrolizumab), an anti-PD-1 precision immunotherapy for surgically resected... Continue Reading


Tagrisso Improves Progression-free Survival in Asian EGFR-mutated Lung Cancer Patients

(January 15, 2018)

CancerConnect News: Tagrisso (osimertinib) improves progression-free survival compared to standard first line therapy in Asian patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC). 1,2 Lung cancer is the number... Continue Reading


FDA Grants Accelerated Approval to Bosulif for Treatment of Newly-Diagnosed Chronic Myelogenous Leukemia

(January 14, 2018)

CancerConnect News: On December 19, 2017, the Food and Drug Administration granted accelerated approval to bosutinib Bosulif (bosutinib) for treatment of patients with newly-diagnosed chronic phase (CP) Philadelphia chromosome positive (Ph+) chronic myelogenous... Continue Reading


Combining T-VEC Herpes Virus With Keytruda Immunotherapy Shows Promise for Treating Advanced Melanoma

(January 12, 2018)

CancerConnect News: UCLA scientists have developed a potential new treatment for melanoma that has shown promising early clinical results.  In a two-year UCLA-led study, nearly two-thirds of people with advanced melanoma responded positively to a treatment... Continue Reading


FDA approves Gazyva for previously untreated follicular lymphoma

(January 11, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to Gazyva (obinutuzumab) in combination with chemotherapy, followed by Gazyva monotherapy in patients achieving at least a partial remission, for the treatment... Continue Reading


Updated Keytruda®/Halaven® Report Encouraging for Treatment of Triple Negative Breast Cancer

(January 10, 2018)

CancerConnect News: The investigative treatment combination including Keytruda® (pembrolizumab) plus Halaven® (eribulin) could provide a potential therapeutic option for patients with advanced triple-negative breast cancer (TNBC) whose disease has advanced... Continue Reading


FDA Approves Opdivo for Adjuvant Treatment of Melanoma

(January 9, 2018)

CancerConnect News: The United States Food and Drug Administration granted regular approval to the anti-PD1 monoclonal antibody, Opdivo (nivolumab) for the adjuvant treatment of patients with melanoma with involvement of lymph nodes or in patients with... Continue Reading


Next Page »